Autoinhibition of Bcr-Abl through Its SH3 Domain

This publication has 37 references indexed in Scilit:

• Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
  New England Journal of Medicine, 2002
• Autoinhibition of c-Abl
  Cell, 2002
• Phosphorylation and structure-based functional studies reveal a positive and a negative role for the activation loop of the c-Abl tyrosine kinase
  Oncogene, 2001
• Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
  Science, 2000
• The P190, P210, and P230 Forms of the BCR/ABL Oncogene Induce a Similar Chronic Myeloid Leukemia–like Syndrome in Mice but Have Different Lymphoid Leukemogenic Activity
  The Journal of Experimental Medicine, 1999
• An intramolecular SH3-domain interaction regulates c-Abl activity
  Nature Genetics, 1998
• Effect of Bcr sequences on the cellular function of the Bcr-Abl oncoprotein
  Oncogene, 1997
• Crystal structure of the Src family tyrosine kinase Hck
  Nature, 1997
• Deletion of the ABL SH3 domain reactivates de-oligomerized BCR-ABL for growth factor independence
  FEBS Letters, 1996
• BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner
  Cell, 1991